Belfast Health and Social Care Trust
caring supporting improving together

FOI/38542

20 October 2026

Migraine Drug Usage Jun-Sep 2026

1. **How many total patients and new patients* have been treated with the following drugs in the past 4 months (June to September 2026):**

	Total Patients	New Patients*
Atogepant	174	64
Erenumab	<5	<5
Eptinezumab	0	0
Fremanezumab	27	27
Galcanezumab	74	10
Rimegepant	84	25
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY	170	14

Eptinezumab first infusion patient to be commenced hopefully before end of October.

* New patients are defined as patients who were not treated with any of the above drugs in the previous 4-month period (February to May 2026).

2. . **How many patients have you treated in the last 4 months (June to September 2026) for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs**:

	Chronic Migraine (15+ headache days/month)
Atogepant	64
Erenumab	<5
Eptinezumab	0
Fremanezumab	27
Galcanezumab	10
Rimegepant	0
Botulinum Toxin	170

3. **How many patients have you treated in the last 4 months (June to September 2026) for ACUTE migraine with**:

- Rimegepant (Vydura) 25 patients
- Atogepant (Aquipta) During this period was only prescribed for Chronic Migraine, October onwards to be used for acute also.

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.